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Abstract: Russia had a high incidence of hepatitis B virus (HBV) infection before the vaccination
campaigns of 1997, 2001, 2007, which targeted newborns, adolescents, and adults, respectively. The aim
of our study was to assess the prevalence of serological markers of HBV infection, associated factors,
and vaccination status among young adults in Arkhangelsk, Northwest Russia. In this cross-sectional,
population-based study, we used a quota sampling method to recruit 1243 adults aged 18–39 years.
Participants completed a self-administrated questionnaire and were tested for hepatitis B markers.
Associations between positivity for markers and selected sociodemographic and behavioral factors
were studied by logistic regression. 10.9% of our participants were positive for at least one marker of
hepatitis B, 1.2% were positive for HBsAg, and 42.1% were negative for all markers. In multivariable
logistic regression analyses, age 30–34 years; lack of self-reported vaccination; and having ≥2 sexual
partners in the last 6 months were associated with positivity for markers of hepatitis B. Hepatitis B
vaccination was confirmed in 46.9% of participants. Although half of our study sample was vaccinated,
four in 10 were still susceptible to infection and more than one participant in 100 showed evidence of an
active infection.
Keywords: population-based study; hepatitis B prevalence; hepatitis B vaccination; Russia
1. Introduction
Infection with hepatitis B virus (HBV) is a major public health problem that is associated with
high morbidity, high mortality, and high treatment-related costs. Approximately one-third of the
global population has serological markers of HBV infection, and more than 240 million people suffer
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from chronic hepatitis B [1]. About 800,000 people die each year from complications related to HBV
infection, such as cirrhosis and liver cancer [2]. HBV can be transmitted through percutaneous or
mucosal exposure to infected blood or other body fluids [3]. It can be transmitted through sexual
contact, both heterosexual and in men who have sex with men; persons with multiple sexual partners;
from mother to child during pregnancy or at birth; among intravenous drug users (IDU); or in
healthcare settings where needles are reused [4]. The prevalence of HBV infection is highest among
adults aged 19–49 years in sub-Saharan Africa and East Asia (>5%). In post-soviet countries and the
Middle East, the prevalence of HBV infection varies between 2% and 4%, while in North America and
Western Europe the prevalence of HBV infection is below 2% [5].
In Russia, the history of acute HBV infection in the post-Soviet era can be divided into two periods.
The first period was characterized by a substantial increase in the incidence of HBV infection from
22.3 per 100,000 in 1993 to 43.8 per 100,000 in 1999. Since 2000, the incidence of acute HBV infection
began to decrease due to the introduction of HBV vaccination, which was first implemented in the
Russian Federation in 1990, but it was only administered to high-risk groups in a few regions [6].
Vaccination of newborns was included in the National Immunization Program in 1997, and vaccination
of 13-year-olds in 2001. Despite these measures, the incidence of acute HBV infection in Russia
remained high (10.0 per 100,000 in 2004). So, in 2007, the vaccination of the adult population was
implemented as a part of the national project “Health” [7]. Since then, more than 70 million people,
approximately 50% of the total population, have been vaccinated, and the incidence of acute HBV
infection decreased to 1.1 per 100,000 in 2015. Registration of chronic HBV infection was initiated
in 1999; in 2001 the incidence of chronic HBV infection was 16.0 per 100,000 and by 2015, this number
had decreased to 10.8 per 100,000 [8]. According to official statistics, the incidence of both acute and
chronic forms of HBV infection in the country is the highest in the age group 20–39 years [8].
In May 2016, the World Health Organization (WHO) formulated the first Global Health Sector Strategy
on Viral Hepatitis, with the stated aim to eliminate these infections. Ten core indicators were proposed to
control the spread of these infections, such as prevalence of chronic HBV infection, the number of people
living with HBV infection, and coverage of a third dose of HBV vaccine among infants [9]. This strategy
has two targets that are to be achieved by 2030: reduction of the incidence of chronic HBV infection by 90%
and reduction of mortality from HBV infection by 65%. The WHO Regional Office for Europe and the
European Centre for Disease Prevention and Control assessed the availability of data for each of the core
indicators and concluded that they are insufficient to assess the epidemiological burden in many countries
in the European region. Therefore they recommended seroprevalence surveys to monitor the prevalence of
viral hepatitis, including undiagnosed infections [10].
The data on serological markers of HBV infection and associated factors in Russia are scarce; we
identified only one study in the international peer-reviewed literature [11]. However, the sample in
that study consisted of blood donors and patients from outpatient clinics, with questionable external
validity for the general population. The Arkhangelsk Region is situated in Northwest Russia and has
an incidence of chronic HBV infection that is similar to the average incidence in Russia as a whole [12].
To support preventive efforts against HBV, the aim of our study was to assess the prevalence of
serological markers of HBV infection, associated factors, and vaccination status among young adults
in Arkhangelsk City, Northwest Russia.
2. Materials and Methods
2.1. Study Population and Study Design
This population-based cross-sectional study was a part of a large Russian-Norwegian project [13].
The study was carried out in Arkhangelsk City, which has a population of about 350,000. Census data were
not available for research purposes, thus the study sample was drawn from the general population using a
quota sampling method [14]. The Agency on Social Research in Arkhangelsk has a database of all cellphone
numbers in the city, as well as population-based group-level census data on sex and age distribution
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(“quotas”) in the eight districts of Arkhangelsk City. Using this information, they phoned eligible persons
aged 18–39 years and informed them about the aims of the study using a script provided by the study
team. Those who agreed to participate presented themselves at the University Clinic of the Northern State
Medical University (NSMU) of Arkhangelsk to complete a self-administered questionnaire and provide a
blood sample. The enrollment procedure was described previously in detail [15]. Data collection lasted
from the end of September 2010 until June 2011. Altogether, 4872 respondents were contacted to fulfil
the “quotas” according to gender and age group. Of them, 3973 agreed to participate; however, the study
team ended enrollment after 1265 participants, since this sample size was sufficient according to power
calculations. Twenty-two participants had missing blood test results and were excluded from the analyses,
resulting in a study sample of 1243 participants.
2.2. Description of the Variables
The questionnaire collected information on sociodemographic and socioeconomic factors, sexual
and preventive behavior, alcohol use, history of sexually transmitted infections (STIs) other than HIV,
and history of HIV infection. Participants reported their family income on a scale of 1 to 10, based
on how they thought their income compared to the average income in Arkhangelsk City. We then
categorized these responses as low (1–4), medium (5–7), and high (8–10) income. The description of
most variables can be found elsewhere [15].
Self-reported HBV vaccination status was divided into “finished vaccination” (three doses of
vaccine), “unfinished vaccination” (one or two doses of vaccine), “unvaccinated” (no dose) and
“unknown vaccination status”. Previous blood transfusions, surgery, and ever being a blood donor
were collapsed into one variable and divided into the categories: “no medical procedure”, “one of these
medical procedures”, “two of these medical procedures”, and “all three of these medical procedures”.
Having tattoos was dichotomized into “yes” and “no”. Respondents were asked whether they knew
anyone with HBV infection, and responses were divided into “no”, “yes”, and “don’t know”.
2.3. Serological Testing
Specimens were sent daily to the research laboratory of the NSMU, where they were centrifuged
and frozen at −20 ◦C. Each month, collected serum specimens were transported to the laboratory of
the Regional STI Clinic in Arkhangelsk City, where they were tested for HBV Antigen (HBsAg), HBV
core antibodies (anti-HBc), HBV surface antibodies (anti-HBs) and Hepatitis C IgG+IgM antibodies,
using an enzyme-linked immunosorbent assay.
Blood samples were also tested for herpes simplex virus type 2 by an enzyme-linked
immunosorbent assay for IgG antibodies against the specific HSV-2 glycoprotein g2 [15]. Main results
on the hepatitis C testing are reported elsewhere. All assays were performed according to the
manufacturer’s instructions. All reagents were manufactured by Vector-Best Company (Novosibirsk,
Russia). For the logistic regression analysis participants negative for all serological markers were
considered unvaccinated and never-infected, coded as 0. Participants positive for anti-HBs only
were considered vaccinated, coded as 0. All other combinations of positivity for serological markers
indicated current or previous HBV infection, and were coded as 1 (Table 1).
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Table 1. Prevalence of serological markers of HBV infection and HBV vaccination status in a
population-based study of adults aged 18–39 years, Arkhangelsk City, Russia, 2010–2011.
Serological Markers of HBV
Infection a/Vaccination Interpretation of Lab Results
Males Females Total
HBsAg Anti-HBc Anti-HBs n % n % n %
Negative Negative Negative Uninfected, HBV infection susceptible 252 46.4 272 38.9 524 42.1
Negative Negative Positive Vaccinated 227 41.8 356 50.9 583 46.9
Negative Positive Positive
Current or previous HBV infection
31 5.7 53 7.6 84 6.7
Negative Positive Negative 27 5.0 10 1.4 37 3.0
Positive Positive Negative 5 0.9 1 0.15 6 0.5
Positive Positive Positive 1 0.2 5 0.7 6 0.5
Positive Negative Negative 0 0.0 2 0.3 2 0.2
Positive Negative Positive 0 0.0 1 0.15 1 0.1
Total 543 100 700 100 1243 100
a Serological markers of HBV infection: HBsAg and/or anti-HBc; Abbreviations: HBV: hepatitis B virus;
HBsAg: HBV surface Antigen; anti-HBc: HBV core antibodies; anti-HBs: HBV surface antibodies.
2.4. Statistical Analyses
A sample size of 1042 was required to detect odds ratios (ORs) of two or greater in multiple logistic
regression analysis with up to seven independent variables for the prevalence of the outcome of 5% or
higher with a 95% confidence level. Therefore, we aimed to recruit 1200 subjects, taking into account
potential drop-outs and missing data. Categorical variables were analyzed using Pearson’s chi-squared
tests. Crude and adjusted logistic regression analyses were conducted to assess the association between
positivity for serological markers of HBV infection and potential related factors. All variables that
were significantly associated with positivity for serological markers of HBV or had a p-value < 0.15 in
crude regression analyses were included in the multivariable model, which was used to estimate
adjusted ORs and 95% confidence intervals (CIs). All analyses were performed using Statistical
Package for Social Sciences version 20 (SPSS Inc., Chicago, IL, USA). Like other authors, we didn’t
exclude participants who were positive for anti-HBs only (considered as vaccinated) from analyses of
risk factors [16–18]. There were two reasons for that. Mass vaccination of the adult population started
in 2007, 3 years before our study period. Thus, vaccinated persons were protected only a few years
prior to their participation in the study. Furthermore, there was no screening for HBV infection before
the HBV vaccination program took effect.
2.5. Ethical Approval
The study was conducted in accordance with the Helsinki Declaration and approved by the
Ethical Committee at Northern State Medical University in Arkhangelsk on 15 March 2010 (No. 04/03).
The participants were given an invitation letter with information about study aims and procedures,
and participants were contacted by telephone if they wanted to know their test results. All participants
signed a written informed consent form. Since this was not a clinical, but solely a seroepidemilogical
study, participants were also asked to provide an e-mail address or telephone number by which they
could be contacted and informed in case tests revealed former or present HBV infection. After learning
their laboratory results, 42 participants were referred to a specialist in infectious diseases, free of charge.
3. Results
The study population consisted of 1243 participants, 543 men and 700 women (43.7% and 56.3%,
respectively). Most participants had higher or incomplete higher education (58.9%) and 72.0% belonged
to the medium income group (Table 2).
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Table 2. Prevalence of serological markers of HBV infection and crude associations between positivity
for serological markers of HBV infection and sociodemographic factors in a population-based study of
1243 adults aged 18–39 years, Arkhangelsk City, Russia, 2010–2011.
Variables n % Prevalence (%)Serological Markers of HBV a Crude OR 95% CI
b
Age
18–24 years 497 40.0 7.0 referent
25–29 years 296 23.8 9.8 1.43 0.86–2.40
30–34 years 278 22.4 16.5 2.62 1.64–4.18
35–39 years 172 13.8 15.1 2.35 1.37–4.04
Sex
Men 543 43.7 11.8 referent
Women 700 56.3 10.3 0.86 0.60–1.23
Education
Low (secondary education, 10–11 years or less) 209 16.8 15.8 referent
Average (secondary vocational education) 302 24.3 9.9 0.59 0.35–0.999
High (incomplete higher and higher education) 732 58.9 10.0 0.59 0.38–0.92
Marital status
Single 571 45.9 8.2 referent
Widowed, divorced 86 6.9 14.0 1.81 0.92–3.57
Co-habitation 213 17.1 14.6 1.90 1.17–3.08
Married 373 30.0 12.3 1.57 1.02–2.41
Income c
Low income 1–4 207 16.7 15.5 referent
Medium income 5–7 895 72.0 10.1 0.61 0.40–0.95
High income 8–10 141 11.3 9.9 0.60 0.31–1.18
Total 1243 100 10.9
a serological markers of HBV infection: HBsAg and/or anti-HBc; b significant association in bold; c subjective
estimation by comparing own family income with family income on average in Arkhangelsk; Abbreviations:
HBV: hepatitis B virus; OR: odds ratio; CI: confidence interval; HBsAg: HBV surface Antigen; anti-HBc: HBV
core antibodies.
The prevalence of serological markers of HBV infection in the full sample was 10.9%,
the prevalence among men was 11.8% and among women 10.2% (Table 1). Among our study sample,
46.4% of men and 38.9% of women were negative for all serological markers, 46.9% were positive for
anti-HBs only, indicating that they were vaccinated, 1.2% were positive for HBsAg, and 10.7% were
positive for anti-HBc (Table 1). The characteristics of the participants positive for HBs Ag are presented
in Table 3. Three of the 15 HBAg positive cases had a co-infection with hepatitis C.
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Table 3. The characteristic of the participants positive on HBs Ag (N = 15) in a population-based study












Do not want to answer 1 (6.7%)
Co-infection with hepatitis C virus *
No 12 (80%)
Yes 3 (20%)
Knowing someone with hepatitis B
No 8 (53.3%)
Yes 4 (26.7%)
Do not know 3 (20.0%)








Have you ever had sex with an intravenous drug user?
No 13 (86.7%)
Yes 1 (6.7%)




* positive on IgM + G.
In crude logistic regression analyses, positivity for serological markers of HBV infection was
positively associated with older age, low income, ever smoking, self-reported STI (other than
HIV), reporting ≥2 partners in the last 6 months, and absence of self-reported HBV vaccination.
Higher education was negatively associated with positivity for serological markers of HBV infection,
indicating a protective effect (Tables 2 and 4).
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Table 4. Prevalence of serological markers of HBV infection and crude associations between positivity
for serological markers of HBV infection and behavioral factors in a population-based study of
1243 adults aged 18–39 years, Arkhangelsk City, Russia, 2010–2011.
Variables N % Prevalence (%)Serological Markers of HBV a Crude OR 95% CI
b
Smoking
Never smoked 491 39.5 8.6 referent
Ever smoked 752 60.5 12.5 1.53 1.04–2.24
Binge drinking c
Never 242 19.5 9.1 referent
Ever 1001 80.5 11.4 1.29 0.80–2.08
Self-reported STI (without HSV-2 or HIV)
Never and don’t know 996 80.1 9.5 referent
Yes 247 19.9 16.6 1.89 1.27–2.81
HSV-2 lab test
Negative 1008 81.2 10.3 referent
Positive 234 18.8 13.7 1.38 0.90–2.11
N of sexual partners in last 6 months
0 and 1 941 75.7 9.9 referent
≥2 302 24.3 14.2 1.51 1.03–2.23
Lifetime N of sexual partners
0 and 1 134 10.8 6.7 referent
2–5 424 34.1 9.9 1.53 0.72–3.23
6 and more 685 55.1 12.4 1.97 0.96–4.02
Use of condom during last sexual encounter
Yes d 339 27.3 8.6 referent
No and don’t remember e 904 72.7 11.8 1.44 0.93–2.21
Use of condom with a steady partner
Always d 270 21.7 8.9 referent
Rarely and sometimes 563 45.3 10.7 1.22 0.74–2.01
Never 410 33.0 12.7 1.49 0.89–2.48
Use of condom with casual partner
Always or never had casual partners 1112 89.5 11.0 referent
Sometimes, rarely, never 131 10.5 10.7 0.97 0.54–1.74
Using of injected drugs
Never 1209 97.3 10.8 referent
Ever 34 2.7 14.7 1.42 0.54–3.73
Have you ever had sex with an intravenous drug user?
No 1094 88.0 10.3 referent
Yes 45 3.6 15.6 1.60 0.70–3.67
Don’t know 104 8.4 15.4 1.58 0.90–2.78
Age at sexual debut
≥18 d 517 41.6 9.5 referent
≤17 726 58.4 12.0 1.30 0.90–1.88
Ever having sex with a partner of the same gender
No 1197 96.3 10.9 referent
Yes 46 3.7 13.0 1.23 0.51–2.96
Previous blood transfusions, surgery, ever being blood donor
No medical procedures 551 44.3 10.9 referent
One of these medical procedures 546 43.9 10.3 0.94 0.64–1.38
Two of these medical procedures 128 10.3 13.3 1.25 0.70–2.23
Three of these medical procedures 18 1.4 16.7 1.64 0.46–5.82
Having tattoos
No 1071 86.2 10.6 referent
Yes 172 13.8 13.4 1.31 0.81–2.12
Knowing someone with HBV infection
No 865 69.6 10.2 referent
Yes 184 14.8 14.7 1.52 0.96–2.42
Don’t know 194 15.6 10.8 1.07 0.65–1.77
Vaccination against HBV
Yes, three doses 384 30.9 8.1 referent
Yes, one or two doses 144 11.6 10.4 1.32 0.69–2.53
Don’t know 380 30.6 11.1 1.42 0.87–2.30
No 335 27.0 14.3 1.90 1.18–3.07
“Vaccination against HBV is necessary”
Agree and tend to agree 1140 91.7 10.7 referent
Disagree and tend to disagree 44 3.5 15.9 1.58 0.69–3.62
Don’t know 59 4.7 11.9 1.12 0.50–2.53
a = serological markers of HBV infection: HBsAg and/or anti-HBc. b = significant association in bold. c = drinking
6 or more units in one occasion. d: Includes 18 participants reporting no sexual debut. e: Includes 11 participants
who did not remember. Abbreviations: HBV: hepatitis B virus; OR: odds ratio; CI: confidence interval; STI: sexually
transmitted infection; N: number; herpes simplex virus type 2 (HSV-2), HBsAg: HBV surface Antigen; anti-HBc: HBV
core antibodies.
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In addition, in crude logistic analyses, several well-known behavioral risk factors were positively
associated with positivity for serological markers of HBV infection, although these associations were
not significant, i.e., intravenous drug use and sex with intravenous drug users; early age at sexual debut;
sex with a partner of the same gender; not using condoms; two or more previous medical procedures;
having tattoos; knowing someone with HBV infection; and not considering HBV vaccination necessary.
The prevalence of serological markers of HBV infection in these groups was higher compared to their
counterparts without these factors. Among the 543 men in our study, 18 (3.3%) reported having sex
with a partner of the same gender. In this group, the prevalence of serological markers of HBV infection
was 16.7% (95% CI 5.84–39.23), and the crude OR for being positive for serological markers of HBV
infection was 1.5 (95% CI 0.42–5.36). The prevalence among men having sex with men was the highest
prevalence found in this study, together with those who reported three medical procedures. This group
counted also only 18 persons, 16.7% were positive for serological markers for HBV infection, and crude
OR was 1.64 (95% CI 0.46–5.82) The prevalence of serological markers of HBV infection among men
who had never had sex with men was 11.7% (95% CI 9.23–14.76). Among women, ever having sex
with a partner of the same gender was not associated with positivity for serological marker of HBV
infection in crude log regression analyses (OR = 1.02; 95% CI 0.30–3.48).
In our study sample, 42.5% of participants reported that they had received at least one dose of
HBV vaccine, and 30.6% did not know whether or not they were vaccinated; however, in the latter
group, 43.2% had isolated anti-HBs antibodies. Serological markers of HBV infection were found
among 8.4% of men and 7.9% of women who reported receiving three doses of HBV vaccine (Table 2),
and 36% and 26%, respectively, did not know if they were vaccinated against HBV. At the same time,
the vast majority of participants (>90%) agreed or tended to agree that vaccination against HBV was
necessary, and serological testing actually showed that 46.9% were vaccinated.
In the multivariable logistic regression analysis, age 30–34 years, absence of self-reported vaccination,
and having ≥2 sexual partners in the last 6 months were significantly associated with positivity for
serological markers of HBV infection, and self-reported history of STI was borderline significant (Table 5).
Table 5. Serological markers of HBV infection a and correlates by multivariable logistic regression analysis
in a population-based study of 1243 adults aged 18–39 years, Arkhangelsk City, Russia, 2010–2011.
Variables Adjusted OR 95% CI b
Age
18–24 years Referent
25–29 years 1.10 0.63–1.94
30–34 years 1.99 1.15–3.43
35–39 years 1.68 0.89–3.16
Education
Low (secondary education (10–11 years) or less) Referent
Average (secondary vocational education) 0.61 0.35–1.06
High (incomplete higher and higher education) 0.75 0.46–1.22
Marital status
Single Referent




Low income 1–4 Referent
Medium income 5–7 0.69 0.44–1.09
High income 8–10 0.70 0.35–1.41
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Table 5. Cont.
Variables Adjusted OR 95% CI b
Smoking
Never smoked Referent
Ever smoked 1.25 0.81–1.91
Vaccination against HBV
Yes, three doses Referent
Yes, one or two doses 1.36 0.70–2.66
Don’t know 1.40 0.84–2.33
No 1.68 1.02–2.77
Self-reported STI (without HSV-2 or HIV)





No. of sexual partners in the last 6 months
0 and 1 Referent
≥2 1.61 1.02–2.54
Lifetime no. of sexual partners
0 and 1 Referent
2–5 1.32 0.61–2.86
6 and more 1.14 0.52–2.49
Use of condom during last sexual encounter
Yes d Referent
No and don’t remember e 1.20 0.67–2.15
Use of condom with a steady partner
Always d Referent
Rarely and sometimes 0.93 0.49–1.75
Never 0.93 0.46–1.87
Have you ever had sex with IDU?
No Referent
Yes 1.16 0.48–2.81
Don’t know 1.18 0.64–2.19
Knowing someone with HBV infection
No Referent
Yes 1.48 0.91–2.41
Don’t know 0.99 0.59–1.68
a Serological markers of HBV infection: HBsAg and/or anti-HBc; b Significant association in bold; c Subjective
estimation by comparing own family income with family income on average in Arkhangelsk; d Includes
18 participants reporting no sexual debut; e Includes 11 participants who did not remember; Abbreviations:
HBV: hepatitis B virus; OR: odds ratio; CI: confidence interval; STI: sexually transmitted infection; herpes simplex
virus type 2 (HSV-2), HBsAg: HBV surface Antigen; anti-HBc: HBV core antibodies; IDU: intravenous drug user.
Significant results were marked in bold.
4. Discussion
To our knowledge, our study is the most recent serosurvey on markers of HBV in the general
population of Northwest Russia. It was conducted after the initiation of mass HBV vaccination
programs in the young adult population, and it combined serological markers of HBV infection and
vaccination with data on risk behavior.
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4.1. Prevalence of Serological Markers of Hepatitis B Virus Infection and Vaccination
Fifteen persons in our study sample (six men and nine women, 1.2% of the study sample) tested
positive for HBsAg and could thus infect others. According to World Health Organization classifications,
a prevalence of 1.2% is categorized as a low-prevalence population [3]. Indeed, the prevalence we observed
is comparable with that found in the general population of Spain, Italy, and Greece. The same prevalence
was found in the Moscow region in 2008 among first-time blood donors and people attending outpatient
clinics [11,19]. However, such comparisons should be done with caution, because donors do not always
represent the general population and may have a lower prevalence of HBsAg [20]. According to the regional
Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing in Arkhangelsk,
the prevalence of HBsAg among blood donors in the region in 2010–2015 was less than 0.2% [21]; however
the prevalence of HBsAg is several times higher among young adults in Arkhangelsk City in our study.
In the present study, positivity for anti-HBc and/or HBsAg combined with negativity for HBsAg
was considered as “ever being infected” with HBV. The childhood or youth of our participants
coincided with the early post-soviet era. During this period, risk factors for HBV increased in the
population, such as intravenous drug use and a freer sexual lifestyle [22,23]. The situation was
aggravated by the absence of HBV vaccination. The prevalence of anti-HBc was 10.7% in our study.
This figure is lower than that reported from six regions of Russia in 2008 [11]. Our results also fit with
the incidence rate of acute HBV infection in the Arkhangelsk Region, which has decreased more during
last 20 years than in other regions [11,24]. The prevalence of anti-HBc among our participants was
close to that reported in Poland, where 10.3% of adults were positive for this marker [25]. Data from
Tajikistan showed that 30% of 15–24-year-olds are positive for anti-HBc, compared to 47% of adults
aged 20–59 years in China, and 57.4% of adults aged 20–39 years in Nigeria [16,26,27]. Data from other
parts of the world demonstrate that the higher the proportion of the vaccinated population, the lower
the proportion of HBV-infected individuals: in Poland 55% of the adult population is vaccinated,
and in China and Nigeria these values are 23.7% and 7.9%, respectively [16,25,27].
Medical records of our participants were not available for this study, so we asked participants
to self-report their vaccination status. Among them, 42.5% reported having at least one dose of HBV
vaccine (Table 3), but 46.9% were positive for anti-HBs, only, according to laboratory tests (Table 1).
These data correspond pretty well with official statistics, which state that 50% of the adult population
in Arkhangelsk was vaccinated by the beginning of 2011 [28]. The impact of universal vaccination
in Russia was assessed by the researchers from Moscow. According to their estimations, 91–95% of
cases of acute and chronic HBV infection that would otherwise occur are, in fact, prevented by HBV
vaccination [11]. Interestingly, 30.6% of our participants didn’t know whether or not they had been
vaccinated against HBV. By comparison, in a Chinese population-based survey only 9.2% of adults
didn’t know their vaccination status. These data demonstrate another specific feature of Russian
society formulated by Russian sociologists: nowadays young adults in Russia have a relatively low
level of healthcare seeking and a low level of knowledge about their health [29]. Among young adults
in our study, 42.1% were still susceptible to HBV infection, so the mass vaccination campaign for adults
should be continued.
4.2. Factors Associated with Positivity for Serological Markers of Hepatitis B Virus
The prevalence of serological markers of HBV among participants aged 30–39 years was two
times higher than the prevalence in those aged 18–29 years. The same trend was observed for anti-HBc
in the Moscow region [11] and for HBsAg among pregnant women in Bulgaria [30], but it was not
observed in surveys from Nigeria, China, India, and the Lao People’s Democratic Republic [16,31–33].
In our study, participants with low education or income level had a higher prevalence of
serological markers of HBV infection. These markers were negatively associated with higher education
and income variables in crude log regression analyses, indicating a protective effect. In multivariable
analyses these associations were still negative, but they were not significant. Other studies have
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also found a higher prevalence of markers of HBV infection among people with the lowest level of
education [16,18,34] or income [32].
HBV is highly contagious and easily transmitted sexually [5]. In our study participants with
a history of STI and multiple sexual partners (≥2 in the past 6 months) had a higher risk of HBV
infection. For the last 7 years sexual transmission of HBV infection has also been one of the most
common routes of transmission reported in the Arkhangelsk Region [21]. Multiple sexual partners and
a history of STI have been also associated with HBV infection in previous studies [35–37]. Men who
have sex with men are considered a high-risk group [4]. In our study, positivity for serological markers
of HBV was positively associated with belonging to this group, but this association was not significant
in crude regression analyses. This can probably be explained by the small number of individuals in
this risk group. Indeed, the prevalence of markers of HBV infection among men who have sex with
men in our study was close to that observed in the USA (17% versus 19%) [38].
Intravenous drug use is an important risk factor for HBV infection, which is also the case in
Arkhangelsk region [4,21]. In crude logistic regression injecting drug use was associated with seropositivity
of HBV markers (Table 4). However this association was not significant. This might be due to lack of
power and insufficient number of participants recognized themselves as ever being drug users.
4.3. Strengths and Weaknesses of the Study
Due to the cross-sectional design, a temporal relationship between risk behavior and positivity for
markers of HBV could not be established. Moreover, as we investigated the young adult population,
so we cannot generalize our results to neither the whole Russian population nor the entire adult
population of Arkhangelsk City. We asked if the participants knew any with HBV infection, but we
did not ask if family members had present or former HBV infection. Thus, we did not attempt to
assess any HBV transmission from mother to child that might have happened nearly 2–4 decades
ago. This may be considered as limitation of the study. In addition, the study questionnaire contained
sensitive questions, which may have caused social desirability bias due to underreporting of high-risk
behavior [39]. Blood sampling can be seen as unpleasant by some, and may have been a deterrent to
study participation [40]. Our sampling method cannot rule out selection bias, for instance through
recruitment via cellphone owners; therefore generalization of our study results should be avoided.
Participants received compensation high enough to pay for a taxi to and from the clinic, and this likely
secured participation among people with low income.
The main strength of our study is its population-based design, including both sexes. We chose to
study young adults, as this group has the highest risk of getting the infection [8]. Moreover, the most
frequent routes of HBV transmission in the region are sexual transmission, intravenous drug use, beauty
treatments (e.g., tattoos, pedicures, etc.), and from mother to child, and thus relate to this age group [21].
Another benefit of our study is the time period in which we carried out of the investigation—soon after the
completion of mass immunization project in the adult population. Most of the vaccinated adults in Russia
were immunized in 2007–2009. So, in 2010–2011 we had a unique chance to investigate herd immunity and
the association of risk factors for HBV markers in the general population. Most of our participants were
vaccinated only 1–2 years prior to the study; before that they were not protected and were susceptible to
HBV infection. According to the official data, the percentage of vaccinated adults aged 18–35 years was
more than 80% in 2016 [41]. So, now the study of the associations between risk factors and positivity for
HBV markers would be difficult. Another strength of our study is it was designed as a “second-generation
HIV/STI survey”, which combines biological indicators with data on risk behavior to provide information
for HIV/STI preventive efforts [42] and provide useful data for monitoring the situation according to
Global Health Sector Strategy on viral hepatitis [9].
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5. Conclusions
The prevalence of HBV markers in our study was close to that observed in Southern and Eastern
European countries. Although half of our participants were protected against HBV thanks to mass adult
vaccination, more than four in ten were still susceptible to HBV infection and there were individuals
with active HBV infection of whom most did not know that they were infected. Therefore the work of
HBV prevention should be continued at all levels, including federal financial support of free-of-charge
HBV vaccination as part of the National Project “Health”, promotion of the HBV vaccination campaign
at the regional level, and routine work at the local level, i.e., by recommending that physicians test for
and treat HBV infections and encourage their patients to be vaccinated during regular check-ups and
before operations; by using mass media and social networks to spread information about HBV infection;
and by encouraging people to be vaccinated to protect themselves, their partners, and their children.
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